Treatment Patterns and Healthcare Resource Utilization in Patients with FLT3-Mut and FLT3-Wt Acute Myeloid Leukemia: A Multi-Country Medical Chart Study
Bibliographic record
Abstract
Introduction: FLT3 is a frequently mutated gene in acute myeloid leukemia (AML) with two main types of mutations: internal tandem duplication (ITD) and point mutations in the tyrosine kinase domain (TKD). FLT-mut AML is associated with poor prognosis. With the development of new therapies in AML, especially those targeting FLT3-mut, there is a need to understand the current treatment (tx) patterns and healthcare resource utilization (HRU) among AML patients. The current study used real-world data from medical records to evaluate tx patterns and HRU among adult AML patients. Methods: Hematologists and oncologists were recruited from 10 countries (US, Canada, UK, France, Germany, Italy, Spain, Netherlands, Japan, and South Korea) from an established physician panel. Eligible patients were randomly selected by physicians and were categorized into 6 cohorts: 1) newly diagnosed (ND) FLT3-mut patients Results: The study included 1,027 AML patients-183 FLT3-mut and 186 FLT3-wt ND patients Conclusions: Using real-world data of AML patients in multiple countries, this study reveals a considerable amount of heterogeneity of tx pattern, including many tx not consistent with tx guidelines. FLT3-mut patients tended to receive more aggressive tx, consistent with fact that the mutation confers a poor prognosis. It also demonstrates extensive HRU among these patients, particularly among R/R cohorts. The study provides timely evidence to understand the current tx landscape and to highlight the substantial unmet needs among AML patients. Disclosures Griffin: Novartis: Consultancy, Research Funding; Astellas Pharma Global Development: Consultancy. Yang: Analysis Group Inc.: Employment; Novartis Pharmaceutical Corporation: Other: Author is an employee of Analysis Group, which received consulting fees from Novartis for this study. Song: Analysis Group: Employment. Kinrich: Analysis Group: Employment. Bui: Astellas Pharma Global Development: Employment.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.003 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.001 |
| Bibliometrics | 0.002 | 0.004 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".